Crossmark

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

Crossref DOI link: https://doi.org/10.1007/s13300-021-01059-1

Published Online: 2021-05-13

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Al-Saleh, Yousef https://orcid.org/0000-0002-5875-0950
Sabico, Shaun

Al-Furqani, Ahmed

Jayyousi, Amin

Alromaihi, Dalal

Ba-Essa, Ebtesam

Alawadi, Fatheya

Alkaabi, Juma

Hassanein, Mohamed

Al-Sifri, Saud

Saleh, Seham

Alessa, Thamer

Al-Daghri, Nasser M.
Funding

Funding for this research was provided by:

Deanship of Scientific Research, King Saud University
License Information

Text and Data Mining valid from 2021-05-13

Version of Record valid from 2021-05-13
More Information

Article History

Received: 17 February 2021

Accepted: 9 April 2021

First Online: 13 May 2021

Change Date: 23 July 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13300-021-01109-8

Updates are available Correction dated 2021-07-23

Click to view Correction: https://doi.org/10.1007/s13300-021-01109-8